New heart disease test you should order | Thomas Dayspring, Md

Drug Treatments

Current pharmaceutical approaches for lowering lipoprotein levels focus on PCSK9 inhibitors and other drugs like bempedoic acid. Thomas Dayspring explains that while PCSK9 inhibitors can lower lipoprotein(a) levels, they are often used off-label due to lack of FDA approval for this specific purpose 1. He notes that these drugs can improve residual cardiovascular risk when combined with statins, although cost remains a barrier for many patients 1. Dayspring also highlights emerging drugs like movolalapine, which show promise in reducing lipoprotein(a) concentrations by up to 60% 2.

   

Emerging Therapies

Emerging therapies for lipoprotein management include genetic approaches and new drug developments. Thomas Dayspring discusses the potential of genetic interventions that target RNA translation to inhibit the production of harmful proteins 3. He mentions the role of chaperone proteins in lipoprotein(a) synthesis and how inhibiting these proteins could reduce lipoprotein(a) levels 4. Dayspring emphasizes that these therapies are still in early stages, but they offer promising avenues for future treatment options.

   

Lifestyle Impact

Lifestyle interventions, including diet and exercise, may influence lipoprotein(a) levels, though their effectiveness is debated. Thomas Dayspring notes that while enzyme inhibitors like phospholipase have been tested, they have not shown significant results in reducing cardiovascular risk 5. He also discusses the potential impact of fish oil and aspirin, highlighting that their benefits may depend on specific genetic factors 6. Dayspring suggests that lifestyle changes can be part of a broader strategy, but they should be tailored to individual needs and genetic profiles.